Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]
Phathom Pharmaceuticals (PHAT) had its price target raised by Guggenheim from $20.00 to $25.00. They now have a "buy" rating on the stock.
Phathom Pharmaceuticals (PHAT) was given a new $28.00 price target by Stifel Nicolaus.